In this report, we found that addition of thioredoxin reductase 1 (TXNRD1) inhibitor auranofin to the TUSC2/erlotinib combination synergistically enhanced cancer cell death by induction of apoptosis through an increase in ROS. Here, TUSC2 is linked to cancer.